CYCN Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Cyclerion Therapeutics Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerCYCN

Market Cap13.4M

Cash RunwayRunway 6-12 months

Next Catalystn/a

Public Research Snapshot

Cyclerion Therapeutics Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for IW-1973 in Diabetes Mellitus, Type 2 | Hypertension (Phase 2).

Pipeline

Asset	Indication	Modality	Stage	Public Note
CYC-126	neuropsychiatric diseases, beginning	n/a	n/a	Public pipeline row
IW-1973	Diabetes Mellitus, Type 2 \| Hypertension	n/a	Phase 2	Public pipeline row
IW-6463	Other	n/a	Phase 1	Public pipeline row
[14C]-praliciguat	n/a	n/a	Phase 1	Public pipeline row
IW-6463 Tablets	MELAS	n/a	Phase 2	Public pipeline row
[14C]-olinciguat	n/a	n/a	Phase 1	Public pipeline row

Catalyst Preview

No public catalyst rows matched this view yet.

Cash Runway Preview

Estimated cash runway: Runway 6-12 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT03091920	Phase 2	COMPLETED	26	2017-08-03
NCT03795519	Phase 1	COMPLETED	8	2019-02-27
NCT03818295	Phase 1	COMPLETED	8	2019-04-24
NCT03254485	Phase 2	COMPLETED	196	2019-08-19
NCT03217591	Phase 2	COMPLETED	156	2019-08-20
NCT03856827	Phase 1	COMPLETED	110	2019-10-22
NCT04240158	Phase 1	TERMINATED	24	2020-05-22
NCT04475549	Phase 2	TERMINATED	8	2022-01-23

Scientific Context

literature_publication | Transient frontal spectral events from EEG predict antidepressant response to sertraline in depression.
literature_publication | Biological effects of sodium phenylbutyrate and taurursodiol in Alzheimer's disease.
literature_publication | BK channels sustain neuronal Ca(2+) oscillations to support hippocampal long-term potentiation and memory formation.
literature_publication | IK(Ca) channels control breast cancer metabolism including AMPK-driven autophagy.
literature_publication | Cysteine-Rich LIM-Only Protein 4 (CRP4) Promotes Atherogenesis in the ApoE(-/-) Mouse Model.

Want the full CYCN research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.